ANIK
Anika Therapeutics Inc
NASDAQ: ANIK · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$12.39
-18.81% today
Updated 2026-04-29
Market cap
$165.66M
P/E ratio
—
P/S ratio
1.47x
EPS (TTM)
$-0.79
Dividend yield
—
52W range
$8 – $16
Volume
0.1M
WallStSmart proprietary scores
35
out of 100
Grade: D
Sell
Investment rating
2.7
Growth
F8.5
Quality
A2.5
Profitability
F5.7
Valuation
C+3/9
Piotroski F-Score
Weak
3.4
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$17.50
+41.24%
12-Month target
—
—
Intrinsic (DCF)
$37.47
Margin of safety
+72.64%
1 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Altman Z 3.36 — safe zone
+ 72.64% below intrinsic value
+ Debt/equity 0.17x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at -9.64%
- Negative free cash flow $-6.28M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $156.24M | $120.79M | $119.91M | $112.82M | $112.82M |
| Net income | $-14.86M | $-82.67M | $-56.38M | $-10.88M | $-5.06M |
| EPS | — | — | — | — | $-0.79 |
| Free cash flow | $-3.08M | $-7.21M | $-2.33M | $4.36M | $-6.28M |
| Profit margin | -9.51% | -68.44% | -47.02% | -9.64% | -9.64% |
Peer comparison
Smart narrative
Anika Therapeutics Inc trades at $12.39. Our Smart Value Score of 35/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 3.36, it sits in the safe zone. TTM revenue stands at $112.82M. with profit margins at -9.64%. Our DCF model estimates intrinsic value at $37.47.
Frequently asked questions
What is Anika Therapeutics Inc's stock price?
Anika Therapeutics Inc (ANIK) trades at $12.39.
Is Anika Therapeutics Inc overvalued?
Smart Value Score 35/100 (Grade D, Sell). DCF value $37.47.
What is the price target of Anika Therapeutics Inc (ANIK)?
The analyst target price is $17.50, representing +41.2% upside from the current price of $12.39.
What is the intrinsic value of Anika Therapeutics Inc (ANIK)?
Based on our DCF model, intrinsic value is $37.47, a +72.6% margin of safety versus $12.39.
What is Anika Therapeutics Inc's revenue?
TTM revenue is $112.82M.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
3.36 — safe zone.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.47x
ROE-6.71%
Beta0.28
50D MA$14.19
200D MA$10.67
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—